your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Licensed vaccines containing inactivated poliovirus vaccine (IPV) - United States

Vaccine composition	Trade name	Manufacturer	Approved use in ACIP routine schedule*	Comments
IPV	Ipol (Poliovax^Δ)	Sanofi Pasteur	2, 4, 6 to 18 months, and 4 to 6 years^¶	Approved for use in infants, children, and adults^◊
DTaP-HepB-IPV^§	Pediarix	GlaxoSmithKline	2, 4, and 6 months	Approved for first 3 doses of IPV through age 6 years^¥
DTaP-IPV/Hib^‡	Pentacel	Sanofi Pasteur	2, 4, 6, and 15 to 18 months^†	Approved for 4 doses of IPV through age 4 years**
DTaP-IPV^¶¶	Kinrix	GlaxoSmithKline	4 to 6 years	Approved for booster dose at age 4 to 6 years^ΔΔ

* Advisory Committee on Immunization Practices. Full schedule available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5751a5.htm.
¶ In the IPV series, the minimum age for dose 1 is six weeks. The minimum interval is four weeks between dose 1 and 2 and between dose 2 and 3. The minimum interval between dose 3 and 4 is six months. Dose 4 should be administered at age ≥4 years regardless of the number of previous doses. Shorter intervals and earlier start dates lead to lower seroconversion rates; therefore, the minimum age and minimum intervals in the first six months of life are recommended only if the recipient is at risk for imminent exposure to circulating poliovirus (eg, during an outbreak or because of travel to an endemic region).
Δ Not currently distributed in the United States.
◊ Package insert available at www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133479.pdf.
§ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and inactivated poliovirus vaccine combined.
¥ Package insert available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136517.htm.
‡ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and Haemophilus influenzae b conjugate (tetanus toxoid conjugate) vaccine.
† When Pentacel is used to provide four doses at ages 2, 4, 6 and 15 to18 months, an additional booster dose of age-appropriate IPV-containing vaccine (Ipol or Kinrix) should be administered at age 4 to 6 years. This will results in a five-dose IPV series; Pentacel is not indicated for the booster dose at age 4 to 6 years. The minimum interval between dose 4 and dose 5 should be at least six months to optimize booster response.
** Package insert available at www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109810.pdf.
¶¶ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, and inactivated poliovirus vaccine.
ΔΔ Package insert available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094027.htm.

Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination. MMWR Morb Mortal Wkly Rep 2009; 58:829.

Graphic 78224 Version 6.0